ArticleJournal of vascular surgery. Venous and lymphatic disorders2026
Short-term outcomes of ultrasound-assisted catheter-directed thrombolysis and mechanical thrombectomy in management of intermediate-risk pulmonary embolism.
Article in Journal of vascular surgery. Venous and lymphatic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to compare preoperative right ventricle-to-left ventricle (RV/LV) ratios by computed tomography angiography (CTA) and echocardiography and evaluate treatment outcomes of ultrasound-assisted catheter-directed thrombolysis (USAT) or mechanical thrombectomy (MT) in patients with intermediate-risk pulmonary embolism (PE).
methodsWe retrospectively identified patients treated for intermediate-risk PE from 2018 to 2023 defined by systolic blood pressure (BP) >90 mmHg and right ventricle dysfunction defined by RV/LV ratio >0.9 via echocardiogram. RV/LV ratios were also evaluated on diagnostic CTA for comparison to echocardiogram values. Patients underwent USAT or MT based on thrombus location and contraindications to thrombolysis. Primary outcomes were intensive care unit (ICU) length of stay (LOS), hospital LOS, and 30-day and 1-year survival. Secondary outcomes included RV/LV change post-treatment on echocardiography, concomitant deep vein thrombosis (DVT), elevated cardiac biomarkers, blood transfusion, history of DVT/PE or malignancy, and imaging modality comparison in determination of RV/LV and RV/LV changes.
resultsOf 120 patients from a single center treated for intermediate-risk PE, 100 underwent USAT and 20 MT. There was no difference in ICU LOS (2.4 vs 2.6 days; P = .67) or hospital LOS (4.8 vs 5.7 days; P = .41) for USAT and MT, respectively. There was no difference in 30-day (98% vs 100%), or 1-year survival (96% vs 90%). MT patients had greater incidence of blood transfusion (25% vs 5%; P = .011). CTA overestimated RV/LV ratios preoperatively compared with echocardiography (1.4; SD, 0.4 vs 1.3; SD, 0.2; P = .027). Patients undergoing MT were more likely to have identified lower extremity DVT compared with patients undergoing USAT (90% vs 65%; P = .033). Other secondary outcomes showed no significant differences between treatment groups.
conclusionsBoth USAT and MT provide excellent short-term and intermediate outcomes in patients with intermediate-risk PE, similar survival rates, similar post-treatment change in right heart dysfunction, and comparable ICU and hospital stays. MT is associated with higher transfusion rates, so caution should be exercised in patients felt to be at risk from further blood loss. These findings support individualized, anatomy- and risk-based selection of catheter-based therapy within a multidisciplinary PE response framework.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.